Monitor the final offering size and pricing when announced — the degree of dilution will determine near-term price pressure. The strong clinical data and revenue growth provide fundamental support, but the capital raise signals cash burn continues. Watch for the Q3 10-Q filing for finalized financials.
Price Chart
Executive Summary
Verastem is conducting a dilutive underwritten public offering of common stock and pre-funded warrants, with pricing and size still TBD. The filing follows a strong preliminary Q3 2026 earnings update (net product revenue estimated at $23.9M-$24.1M, up from $11.2M YoY) and positive VS-7375 clinical data, but the capital raise itself creates immediate dilution for existing shareholders. Proceeds will fund continued clinical development of VS-7375 and general corporate purposes.
Key Facts
- Offering of common stock and pre-funded warrants; pricing and share count are undisclosed (placeholder values).
- Last reported sale price on October 13, 2026 was $7.45 per share.
- Net tangible book value as of June 30, 2026 was $34.1 million ($0.38 per share).
- Preliminary Q3 2026 net product revenue estimated at $23.9M-$24.1M (vs $11.2M in Q3 2025).
- Cash, cash equivalents and investments as of September 30, 2026 estimated at $172.8 million (vs $137.7 million at September 30, 2025).
- CEO transition: Daniel Paterson retiring effective January 1, 2027; Michael Bailey to become CEO.
- FDA accepted Blister Pack NDA for priority review on October 7, 2026.
- VS-7375 showed 41% confirmed ORR in 2L+ PDAC and 43% confirmed ORR in 2L+ NSCLC at data cutoff October 7, 2026.
- Lock-up agreements with underwriters for 60 days post-offering for executive officers and directors.
Financial Impact
Undisclosed offering size; immediate dilution to existing shareholders as offering price will be above net tangible book value of $0.38 per share. Preliminary Q3 revenue of ~$24M and cash of $172.8M provide context for capital need.
Risk Factors
- Immediate and substantial dilution to existing shareholders from the offering.
- Offering price and size are undisclosed — uncertainty about total capital raised and per-share impact.
- Preliminary financial results are unaudited and subject to revision.
- CEO transition adds leadership uncertainty through early 2027.
- Biotech sector risk: clinical-stage pipeline (VS-7375) still in Phase 1/2; no guarantee of eventual approval or commercial success.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-115875 |
| Document: 0001104659-26-115875-index-headers.html | 0001104659-26-115875 |
| Document: 0001104659-26-115875-index.html | 0001104659-26-115875 |
| Document: 0001104659-26-115875.txt | 0001104659-26-115875 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $9.23 | awaiting T+60 | — | $10.00 (−8.34%) |
Oct 14, 2026 12d ago | 424B5 | $9.23 | awaiting T+60 | — | $10.00 (−8.34%) |
Oct 14, 2026 12d ago | 424B5 | $9.23 | awaiting T+60 | — | $10.00 (−8.34%) |
Oct 14, 2026 12d ago | 8-K | $7.71 | awaiting T+60 | — | $10.00 (+29.70%) |
Oct 2, 2026 24d ago | Insider Cluster | $8.00 | awaiting T+60 | — | $10.00 (−25.00%) |
Jun 23, 2026 17w ago | 8-K | $3.85 $7.55 | ▲ +96.10% | ▲ +93.27% | $10.00 (+159.74%) |
Jun 17, 2026 18w ago | 8-K | $4.17 $7.32 | ▲ +75.54% | ▲ +72.39% | $10.00 (+139.81%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.10 $8.08 | ▲ +97.07% | ▲ +93.81% | $10.00 (+143.90%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.94 $8.20 | ▲ +108.12% | ▲ +103.73% | $10.00 (+153.81%) |
May 27, 2026 21w ago | 3 | $4.29 $6.89 | ▲ +60.61% | ▲ +58.87% | $10.00 (+133.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers